The company said it has responded to the FDA’s Office of Prescription Drug Promotion after receiving a notice on March 13 about its promotional content.
Biotech ETFs rally. IBB, ARKG, SBIO, BBC, CANC and BBP soar as Fed rate cut optimism, FDA approvals, deals and cheaper valuations drive the space in 2025.